| Lyke, Kirsten E |
NCT04889209: Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines |
|
|
| Completed | 1/2 | 867 | US | Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1 | National Institute of Allergy and Infectious Diseases (NIAID) | COVID-19 | 06/23 | 06/23 | | |
| Active, not recruiting | 1 | 72 | US | Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID), HTNV vaccine using TDS ID, Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), HTNV vaccine using TDS IM, Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), PUUV vaccine using TDS ID, Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), PUUV vaccine using the TDS IM, Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), HTNV/PUUV vaccines using the TDS ID, Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM), HTNV/PUUV vaccines using the TDS IM | U.S. Army Medical Research and Development Command | Hantaan Virus Disease, Puumala Virus | 12/22 | 04/23 | | |
NCT05604521: A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI |
|
|
| Terminated | 1 | 31 | US | PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline, Placebo | Sanaria Inc., University of Maryland, Baltimore, National Institute of Allergy and Infectious Diseases (NIAID) | Malaria, Malaria,Falciparum | 09/23 | 09/23 | | |
| Completed | 1 | 29 | US | Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose, Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Medium Dose, Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - High Dose | University of Maryland, Baltimore, Medical Technology Enterprise Consortium (MTEC) | Dengue | 01/24 | 01/24 | | |
| Boyce, Colleen |
NCT04078022: Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine |
|
|
| Completed | 2 | 58 | US | SF2a-TT15 Shigella Vaccine, Placebo, S. flexneri 2a strain 2457T Challenge Agent | University of Maryland, Baltimore | Shigella | 01/23 | 01/24 | | |
| Barnes, Robin |
NCT03705585: CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera |
|
|
| Recruiting | 4 | 240 | US | Vivotif Typhoid Oral Vaccine, Ty21a Typhoid Oral Vaccine, Vaxchora, CVD 103-HgR | University of Maryland, Baltimore | Typhoid and/or Cholera Vaccination | 05/25 | 05/25 | | |
| Recruiting | 4 | 150 | US | Vivotif Typhoid Oral Vaccine, Ty21a Typhoid Oral Vaccine | University of Maryland, Baltimore | Risk Reduction | 05/25 | 05/25 | | |
| Holian, Susan |
NCT03705585: CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera |
|
|
| Recruiting | 4 | 240 | US | Vivotif Typhoid Oral Vaccine, Ty21a Typhoid Oral Vaccine, Vaxchora, CVD 103-HgR | University of Maryland, Baltimore | Typhoid and/or Cholera Vaccination | 05/25 | 05/25 | | |
| Recruiting | 4 | 150 | US | Vivotif Typhoid Oral Vaccine, Ty21a Typhoid Oral Vaccine | University of Maryland, Baltimore | Risk Reduction | 05/25 | 05/25 | | |
